Back

Comparative effectiveness of mineralocorticoid receptor antagonists in cardiorenal and metabolic disease

30 August 2026 (15:15 - 15:45)
Organised by: Logo
Congress Presentation Part of: Pharmacotherapy of aldosterone signalling and drug‑related myocardial injury Aldosterone Antagonists ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Associate Professor Alexandros Briasoulis

National & Kapodistrian University of Athens Medical School, Athens (Greece)

3 More presentations in this session

Presentation thumbnail
Effect of finerenone on cardiac remodeling and exercise capacity in patients with anterior ST-elevation myocardial infarction underwent primary percutaneous coronary intervention
Doctor S. Sungkar (Semarang, ID)
Abstract Slides Video
Presentation thumbnail
Development and validation of a Frusemide Card to guide self-titration of oral frusemide in the outpatient setting
Doctor S. Hussin (Kota Bharu, MY)
Abstract Slides Video
Presentation thumbnail
Effect of coramitug on diuretic use in transthyretin amyloid cardiomyopathy (ATTR CM): a post-hoc analysis from a phase 2 randomised, placebo-controlled study
Professor S. Gottlieb (Baltimore, US)
Abstract Slides Video

Access the full session

Session thumbnail
Pharmacotherapy of aldosterone signalling and drug‑related myocardial injury

The Event

Event poster

ESC Congress 2026

30 August 2026 15:15 CET
You may be interested in
thumbnail
Congress Presentation
Finerenone versus spironolactone in HFpEF patients with type 2 diabetes and CKD: a real-world comparative analysis
30 August 2026
thumbnail
Congress Presentation
Timing of sacubitril/valsartan initiation and cardiovascular outcomes in anthracycline-treated cancer patients
29 August 2026
thumbnail
Congress Presentation
Comparative outcomes of catheter ablation for atrial fibrillation in heart failure patients with pulmonary hypertension: a propensity-matched analysis
31 August 2026
thumbnail
Congress Presentation
PRO-C6 and endotrophin are associated with cardiac remodelling and adverse outcomes in HFpEF: data from the prospective NETDiamond cohort
28 August 2026

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources